The evaluation of H2A1B, MIF and TPM1 levels in other biological fluid of low invasiveness collection, such as blood or saliva, could be a possible alarm bell for an early diagnosis of GBM recurrence to be investigated in a future study. Here, TPM1 is linked to glioblastoma.